PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals.

[1]  G. Palomaki,et al.  Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. , 2013, The Journal of urology.

[2]  J. Ward,et al.  PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. , 2013, The Journal of urology.

[3]  J. Futterer,et al.  Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI , 2013, International journal of molecular sciences.

[4]  G. Palomaki,et al.  PCA3 Testing for the Diagnosis and Management of Prostate Cancer , 2013 .

[5]  J. Schalken,et al.  Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. , 2013, Anticancer research.

[6]  K. Chevli,et al.  Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients , 2013, The Prostate.

[7]  K. Pummer,et al.  Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness , 2013, The Prostate.

[8]  F. Aragona,et al.  PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients. , 2012, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[9]  R. Montironi,et al.  Transrectal ultrasound (TRUS) and TRUS-biopsy accuracy in potential candidates for PRIAS active surveillance protocol. , 2012, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[10]  R. Autorino,et al.  Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[11]  F. Fraggetta,et al.  PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? , 2012, International braz j urol : official journal of the Brazilian Society of Urology.

[12]  F. Aragona,et al.  PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. , 2011, Anticancer research.

[13]  T. D. de Reijke,et al.  Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. , 2011, The Journal of urology.

[14]  M. Roobol.  Contemporary role of prostate cancer gene 3 in the management of prostate cancer , 2011, Current opinion in urology.

[15]  L. Salomon,et al.  Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. , 2011, European urology.

[16]  A. Parwani.  External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome , 2011 .

[17]  A. Haese*,et al.  Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. , 2011, European urology.

[18]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[19]  G. Andriole,et al.  PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. , 2010, The Journal of urology.

[20]  R. V. D. van den Bergh,et al.  Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. , 2010, European urology.

[21]  J. Witjes,et al.  Predictive value of PCA3 in urinary sediments in determining clinico‐pathological characteristics of prostate cancer , 2010, The Prostate.

[22]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[23]  P. Troncoso,et al.  PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. , 2008, The Journal of urology.

[24]  Seongjoon Koo,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[25]  P. Kantoff,et al.  Active Surveillance for Early-stage Prostate Cancer Review of the Current Literature , 2008 .

[26]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[27]  M. Garnick,et al.  Prostate Cancer: Screening, Diagnosis, and Management , 1993, Annals of Internal Medicine.